FLT1 and diffuse large B-cell lymphoma: Our goal was to evaluate the clinical impact of the expression of VEGF isoforms, VEGF121, VEGF165, VEGF189, and their receptors VEGFR-1 and R-2 in a cohort of patients with relapsed/refractory DLBCL prospectively treated in the international multicentre trial CORAL (Collaborative Trial in Relapsed Aggressive Lymphoma) [11].